

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 May 2020 (14.05.2020)



(10) International Publication Number
WO 2020/097266 A1

(51) International Patent Classification:

<i>C07D 401/06</i> (2006.01)	<i>C07D 417/06</i> (2006.01)
<i>C07D 401/14</i> (2006.01)	<i>C07D 417/14</i> (2006.01)
<i>C07D 403/06</i> (2006.01)	<i>C07D 471/04</i> (2006.01)
<i>C07D 403/14</i> (2006.01)	<i>A61P 21/00</i> (2006.01)
<i>C07D 405/06</i> (2006.01)	<i>A61P 25/16</i> (2006.01)
<i>C07D 413/06</i> (2006.01)	<i>A61K 31/501</i> (2006.01)
<i>C07D 413/14</i> (2006.01)	

(21) International Application Number:

PCT/US2019/060157

(22) International Filing Date:

06 November 2019 (06.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/756,553 06 November 2018 (06.11.2018) US

(71) Applicant: **EDGEWISE THERAPEUTICS, INC.**
[US/US]; 3415 Colorado Avenue, Boulder, Colorado 80303 (US).

(72) Inventors: **HUNT, Kevin**; 3415 Colorado Avenue, Boulder, Colorado 80303 (US). **KOCH, Kevin**; 3415 Colorado Avenue, Boulder, Colorado 80303 (US). **RUSSELL, Alan**; 3415 Colorado Avenue, Boulder, Colorado 80303 (US). **SCHLACHTER, Stephen**; 3415 Colorado Avenue, Boulder, Colorado 80303 (US). **WINSHIP, Paul**; 251 Ballardvale Street, Wilmington, MA 01887 (US). **STEELE, Chris**; 251 Ballardvale Street, Wilmington, MA 01887 (US).

(74) Agent: **MARGULIEUX, Grant W.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304-1050 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PYRIDAZINONE COMPOUNDS AND USES THEREOF




FIGURE 6

(57) Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF- α .

WO 2020/097266 A1